ART BioScience

Therapeutics for Duchenne Muscular Dystrophy

Company Name
Updating Date
Neurotech Category
Market Category
Target Market
Technologies
Company Founded Year
Company Number of Employees
ART BioScience
NeuroPharmacology | NeuroBioTechnology
Biotechnology & Biopharmaceutical
Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis)
Biochemical: pharmacological drugs (Developing drugs)
01/01/2015
"1-10"

ART BioScience is a company based on novel messenger RNA technologies for the development of therapeutics that may potentially change the course of Duchenne Muscular Dystrophy.



ART BioScience was founded by Mr. Oren Ozeri and Mr. Alon Hazan, fathers of two children diagnosed with Duchenne Muscular Dystrophy.